Significant Differences in Capsid Properties and Potency Between Adeno-Associated Virus Vectors Produced in Sf9 and HEK293 Cells-Reference-Cited by-同舟云学术

Significant Differences in Capsid Properties and Potency Between Adeno-Associated Virus Vectors Produced in Sf9 and HEK293 Cells

Published:2023-10-01 Issue:19-20 Volume:34 Page:1003-1021
ISSN:1043-0342
Container-title:Human Gene Therapy
language:en
Short-container-title:Human Gene Therapy

Author:

Giles April¹,Lock Martin¹,Chen Shu-Jen¹,Turner Kevin¹,Wesolowski Gregg¹,Prongay Andrew¹,Petkov Boris N.¹,Olagbegi Kanyin¹,Yan Hanying¹,Wilson James M.¹^ORCID

Affiliation:

1. Gene Therapy Program, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Publisher

Mary Ann Liebert Inc

Subject

Genetics,Molecular Biology,Molecular Medicine

Link

https://www.liebertpub.com/doi/pdf/10.1089/hum.2022.116

Reference39 articles.

1. Manufacturing of recombinant adeno-associated viral vectors for clinical trials

2. Rapid, Simple, and Versatile Manufacturing of Recombinant Adeno-Associated Viral Vectors at Scale

3. Manufacturing and Regulatory Strategies for Clinical AAV2-hRPE65

4. Development and Optimization of AAV hFIX Particles by Transient Transfection in an iCELLis®Fixed-Bed Bioreactor

5. Insect Cells as a Factory to Produce Adeno-Associated Virus Type 2 Vectors

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The state of technological advancement to address challenges in the manufacture of rAAV gene therapies;Biotechnology Advances;2024-11

2. Serotype-agnostic affinity purification of adeno-associated virus (AAV) via peptide-functionalized chromatographic resins;Journal of Chromatography A;2024-10

3. Production of recombinant adeno-associated virus 5 using a novel self-attenuating adenovirus production platform;Molecular Therapy - Methods & Clinical Development;2024-09

4. Producing high-quantity and high-quality recombinant adeno-associated virus by low-cis triple transfection;Molecular Therapy - Methods & Clinical Development;2024-06

5. Characterizing the Biopotency of Truncated Transgene Variants in rAAV8 viral vectors: Essential Considerations for Gene Therapy Applications;2024-04-04